Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: A systematic review

Cost Effectiveness and Resource Allocation

Volumn 9, Issue , 2011, Pages

  Hagenmeyer, Ernst Günther ^a   Koltermann, Katharina C ^a   Dippel, Franz Werner ^b   Schädlich, Peter K ^c  

^a Sanofi Aventis Deutschland GmbH ^*  (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c IGES Institut GmbH   (Germany)

Author keywords

Basal bolus therapy; Health economics; Insulin glargine; Nph; Systematic review; Type 1 diabetes

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; GERMANY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL DECISION MAKING; METABOLIC REGULATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 80053544689     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-9-15     Document Type: Review

References (41)

1. Hirsch IB. Drug therapy: insulin analogues. N Engl J Med Vol 352 2005, (2):174-183.
2. Owens DR, Bolli GB. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008, 10(5):333-349. 10.1089/dia.2008.0023, 18715209.
3. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time action profile of the long acting insulin analog isnulin glargine (HOE901) in comparison with those of NPH insulin anf placebo. Diabetes Care 2000, 23:644-649. 10.2337/diacare.23.5.644, 10834424.
4. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009, 11(4):372-378. 10.1111/j.1463-1326.2008.00976.x, 19267715.
5. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180(4):385-397. 10.1503/cmaj.081041, 2638025, 19221352.
6. Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev 2008, (3):CD006297.
7. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007, 29(8):1607-1619. 10.1016/j.clinthera.2007.08.020, 17919543.
8. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373(9680):2027-2033. 10.1016/S0140-6736(09)60568-7, 19481249.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700. 10.1136/bmj.b2700, 2714672, 19622552.
10. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2008, Chichester: The Cochrane Collaboration and John Wiley & Sons Ltd.
11. Leidl R, Graf von der Schulenburg JM, Wasem J, . eds [Approaches and methods of economic evaluation in health care-an international perspective]. 1999, Baden-Baden: Nomos Verlagsgesellschaft, eds.
12. Aidelsburger P, Felder S, Siebert U. [Health economic short HTA-reports-systematic overview of the methods and implementation]. HTA-Schriftenreihe 2003, 6. Köln: Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information, Rüther A, Dauben H, Warda F.
13. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996, 313:275-283. 2351717, 8704542.
14. Drummond M, Sculpher M, Torrance G. Methods for the economic evaluation of health care programmes 2005, Oxford: Oxford University Press, 3.
15. American Diabetes Association Consensus Panel Consensus statement: Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004, 27(9):2262-2265. American Diabetes Association Consensus Panel.
16. von Elm E, Altman DG, Egger M, Pocock S, Gotzsche P, Vancenbroucke J, . STROBE Initiative The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007, 147(8):573-577. STROBE Initiative.
17. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004, 22(13):857-876. 10.2165/00019053-200422130-00004, 15329031.
18. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009, 12(4):409-418. 10.1111/j.1524-4733.2008.00489.x, 19900249.
19. Statistisches Bundesamt [International comparison of consumer prices] 2009, Wiesbaden, Germany: Statistisches Bundesamt, Statistisches Bundesamt.
20. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. The Clinical and Cost-effectiveness of Long-Acting Insulin Analogue, Insulin glargine. Assessment Report. ScHARR Rapid Reviews Group 2002, School of Health and Related Research. University of Sheffield.
21. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Canadian Medical Association Journal 2009, 180(4):400-407. 10.1503/cmaj.081180, 2638053, 19221353.
22. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007, 25(3):253-266. 10.2165/00019053-200725030-00007, 17335310.
23. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion, Supplement 2007, 23(1):S7-S19.
24. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004, 8(45):iii. 1-57.
25. Brändle M, Azoulay M, Greiner R. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 and type 2 diabetes in Switzerland. ADA Scientific Session 2009, 7:A408-A409. New Orleans, Louisiana.
26. Hagenmeyer EG, Gothe H, Kulik M, Schiffhorst G, Höer A, Häussler B. Comparison of Cost and Utilisation among Propensity Score Matched Users of Insulin Glargine and Users of NPH Insulin in Type 1 and Type 2 Diabetes 2007, Berlin: IGES Institut GmbH.
27. Brixner DI, McAdam-Marx C. Cost-effectiveness of insulin analogs. Am J Manag Care 2008, 14(11):766-775.
28. Clissold R, Clissold S. Insulin glargine in the management of diabetes mellitus: An evidence-based assessment of its clinical efficacy and economic value. Core Evid 2007, 2(2):89-110. 3012430, 21221178.
29. Leichter S. Is the use of insulin analogues cost-effective?. Adv Ther 2008, 25(4):285-299. 10.1007/s12325-008-0043-9, 18414816.
30. NICE Type 1 diabetes in adults: national clinical guideline for diagnosis and management in primary and secondary care. 2004, 171. London: Royal College of Physicians, NICE.
31. Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson SH, Campbell K. Long-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. 2007, Ottawa: Canadian Agency for Drugs and Technologies in Health.
32. National Institute for Clinical Excellence (NICE) Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine. Technology Appraisal No. 53 2002, London: National Institute for Clinical Excellence (NICE), National Institute for Clinical Excellence (NICE).
33. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000, 23:157-62. 10.2337/diacare.23.2.157, 10868824.
34. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004, 21(11):1213-1220. 10.1111/j.1464-5491.2004.01323.x, 15498088.
35. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes care 2000, 23(5):639. 10.2337/diacare.23.5.639, 10834423.
36. Hagenmeyer EG, Schädlich PK, Koster AD, Dippel FW, Häussler B. [Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues]. Dtsch Med Wochenschr 2009, 134(12):565-570. 10.1055/s-0029-1208087, 19277932.
37. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006, 22(8):1523-1534. 10.1185/030079906X115757, 16870077.
38. National Institute for Clinical Excellence (NICE) Guide to the methods of technology appraisal. 2008, London: National Institute for Clinical Excellence (NICE), National Institute for Clinical Excellence (NICE).
39. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005, 8(1):10-23. 10.1111/j.1524-4733.2005.03070.x, 15841890.
40. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276(16):1339-1341. 10.1001/jama.276.16.1339, 8861994.
41. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005, 10(4):245-250. 10.1258/135581905774414187, 16259692.